ClinicalTrials.gg
CompletedNCT00503425Updated Aug 15, 2017Results posted

A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

A Phase 3 interventional study of Rituximab [MabThera/Rituxan] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 16 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Jun 2005, registered Jul 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
215
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
24th of 63
215 · median 159
Started
2005
with 2 others
Phase 3
27 of 63
1 open now
Registered
15th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 24th largest by enrollment, is one of 3 that started in 2005, is one of 27 in phase 3, and was the 15th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This single arm study will evaluate the safety and efficacy of MabThera in participants with active rheumatoid arthritis who have had an inadequate response to prior treatment with DMARDs and/or anti-TNF alpha agent. Participants will be treated with MabThera 1000 milligrams (mg) intravenously (IV) on days 1 and 15. Participants were followed every 8 weeks to complete 24 weeks of follow-up. After completion of the Week 24 visit, the participants were followed every 3 months for up to 18 months for an overall study duration of 24 months (104 weeks). After week 36, eligible participants who achieve moderate or good response according to the European League Against Rheumatism (EULAR) response criteria will receive re-treatment with MabThera. Participants will receive concomitant treatment with DMARDs, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics throughout the study period. The anticipated time on study treatment is 2 years, and the target sample size is 200 participants.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

During study entry

  • Able and willing to give written and comply with the requirements of the study protocol;
  • Participants with Rheumatoid Arthritis (RA) for at least 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of RA;
  • Receiving treatment on an outpatient basis;
  • Experienced an inadequate response to previous or current treatment with DMARDs because of toxicity or inadequate efficacy;
  • Disease activity score (DAS28) greater than or equal to (>=) 3.2 at screening and baseline visit.
  • Age >= 18 years;
  • Participants of (males and females) using a reliable means of (for example [e.g.] contraceptive pill, intrauterine device, physical barrier);
  • Female participants with - a negative urine pregnancy test within two weeks prior to first rituximab treatment.

During Re-Treatment

  • Achieved moderate or good response according to the EULAR response criteria during any visit including visits in the post-treatment period;
  • DAS28 >=3.2;
  • The participants has not been withdrawn into the safety follow-up at any time pre or post Week 24;
  • 36 weeks or more have passed since the participant's first rituximab infusion;
  • No evidence of any new medical condition or laboratory test results;
  • In participants who were known to be positive to core antibody (HBcAb) - documented negative hepatitis B viral DNA (HBV-DNA) test and (AST)/alanine aminotransferase (ALT) less than or equal to (\<=) 2.5x (ULN) within the last 12 weeks;
  • Female participants with childbearing potential - a negative urine pregnancy test immediately prior to treatment initiation.

Exclusion Criteria:

  • Rheumatic disease other than RA, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Sjogren's syndrome with RA was permitted;
  • Functional class IV as defined by the ACR Classification of Functional Status in RA;
  • History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic rheumatic disorder disorder (e.g., inflammatory bowel disease, scleroderma, inflammatory myopathy);

Excluded Previous/Concomitant Medications

  • Previous or concurrent treatment with any anti TNF-alpha therapy;
  • Treatment with any agent within 4 weeks of screening;
  • Previous treatment with any cell depleting therapies excluding rituximab, including investigational agents;
  • Immunization with a within 4 weeks prior to the baseline visit.

Exclusions for General Safety

  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies;
  • Significant cardiac or pulmonary disease (including obstructive pulmonary disease).
  • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders.
  • Known active bacterial, viral, fungal, mycobacterial or other infection (including tuberculosis, or atypical mycobacterial disease, but excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening;
  • History of recurrent significant infection or history of recurrent bacterial infections;
  • Primary or secondary immunodeficiency (history of, or currently active);
  • Active cancer, including solid tumors and hematologic (except basal cell or squamous cell carcinoma of the skin that have been excised and cured);
  • Pregnant women or nursing (breast feeding) mothers;
  • Participants with lack of peripheral venous access;

Laboratory Exclusion Criteria (at Screening)

  • Positive tests for hepatitis B surface antigen (HBsAg) and/or positive tests for HBcAb associated with detectable HBV-DNA or antibody (HCAb) and hepatitis C viral RNA (HCV-RNA).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    1

    Drug: Rituximab [MabThera/Rituxan]

Interventions

  • DrugRituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000 mg IV on days 1 and 15

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants with non-serious AEs was exclusive of SAEs.

    Time frame: Baseline up to study withdrawal or follow-up (Approximately 104 weeks)

Secondary outcomes

  1. Mean Change From Baseline in Disease Activity Score Based on 28 Joints (DAS 28) at Week 24

    DAS28 score is a measure of participant's disease activity calculated using tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], participant's global assessment of disease activity (PGH) \[visual analog scale (VAS): 0=no disease activity to 100=maximum disease activity\] and erythrocyte sedimentation rate (ESR). DAS28 was calculated according to following formula: 0.56 multiplied by (\*) square root (√) of TJC\] plus (+) \[0.28\*√SJC\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*PGH\]. Total possible score of 0 to approximately 10, where higher scores represented higher disease activity. Scores below 2.6 indicated clinical remission, score of less than or equals to (\</=) 3.2 indicated low disease activity, score of \</=5.1 indicated moderate disease activity, scores above 5.1 indicated high or severe disease. Rituximab was administered as needed during episodes of inflammation for up to 5 courses. Change from baseline in DAS28 to Week 24 was reported for all 5 courses.

    Time frame: Baseline, Week 24

  2. Percentage of Participants Whose DAS28 Improved by Greater Than (>) 1.2 at Week 24

    DAS28 score is a measure of participant's disease activity calculated using TJC28, SJC28, PGH \[VAS: 0=no disease activity to 100=maximum disease activity\] and ESR. DAS28 was calculated according to following formula: \[0.56\*√TJC\] + \[0.28\*√SJC\] + \[0.70\*ln ESR\] + \[0.014\*PGH\]. Total possible score of 0 to approximately 10, where higher scores represented higher disease activity. Scores below 2.6 indicated clinical remission, score of \</= 3.2 indicated low disease activity, score of \</= 5.1 indicated moderate disease activity, and scores above 5.1 indicated high or severe disease. Rituximab was administered as needed during episodes of inflammation for up to 5 courses. Change from baseline in DAS28 to Week 24 was reported for all 5 courses. Participants whose DAS28 score improved by 1.2 score were reported.

    Time frame: Week 24

  3. Percentage of Participants With EULAR DAS 28 Response at Week 24

    Clinical response was assessed according to EULAR categorical DAS28 response criteria, which defined clinically meaningful improvement at Week 24. EULAR response was based on change from baseline (COB) in DAS28 score and also on actual DAS28 score, at Week 24. DAS28 score= participant's disease activity calculated using TJC28, SJC28, PGH \[VAS: 0=no disease activity to 100=maximum disease activity\] and ESR. DAS28 was calculated by following formula: 0.56\*√TJC+(0.28\*√SJC)+(0.70\*ln ESR)+(0.014\*PGH). Total possible score=0-10, higher scores represented higher disease activity. Scores below 2.6: clinical remission, \</=3.2: low disease activity, \</=5.1: moderate disease activity, above 5.1: severe disease. EULAR Good response: DAS28\</=3.2; COB\<-1.2. Moderate response: DAS28\</=3.2 or \>3.2 to \</=5.1 or \>5.1; COB \<-1.2 or \<-0.6 to greater than or equal to (\>/=)-1.2. No response: DAS28 \</=3.2 or \> 3.2 to \</=5.1 or \>5.1; COB \<-0.6 to \>/=-1.2 or \>/=-0.6. EULAR response was reported for 5 courses.

    Time frame: Week 24

  4. Change From Baseline in Bone Density Score at Weeks 48 and 104

    Bone density or bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD test results are compared to the ideal or peak BMD of a healthy 30-year-old adult, and results are provided as T-score. A score of 0 means BMD is equal to the norm for a healthy young adult. Differences between observed BMD and that of the healthy young adult norm are measured in units called standard deviations (SDs). The more standard deviations below 0, indicated as negative numbers, lower the BMD higher the risk of fracture. SD + 1 to -1 indicates normal BMD; SD between -1 to -2.5 indicates low bone mass, SD -2.5 or lower indicates osteoporosis. Change in bone density was measured in participants who were not treated with biphosphonates by Dual Energy X-Ray Absorptiometry. Change in bone density was assessed at baseline and at Weeks 48 and 104. Change from baseline in bone density score was reported for all 5 courses.

    Time frame: Baseline, Weeks 48 and 104 (End of treatment)

07

Results

Posted Jun 23, 2016

Participant flow

Participant flow — Overall Study
MilestoneRituximab
Started215
Completed161
Not completed54
Withdrew: Participant files lost6
Withdrew: Adverse event5
Withdrew: Lack of efficacy25
Withdrew: Withdrawal by subject8
Withdrew: Lost to follow-up3
Withdrew: Death3
Withdrew: Missing data/unknown4

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Number of participants with non-serious AEs was exclusive of SAEs.

Time frame:
Baseline up to study withdrawal or follow-up (Approximately 104 weeks)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsRituximab
AEs176
SAEs70
SecondaryMean Change From Baseline in Disease Activity Score Based on 28 Joints (DAS 28) at Week 24

DAS28 score is a measure of participant's disease activity calculated using tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], participant's global assessment of disease activity (PGH) \[visual analog scale (VAS): 0=no disease activity to 100=maximum disease activity\] and erythrocyte sedimentation rate (ESR). DAS28 was calculated according to following formula: 0.56 multiplied by (\*) square root (√) of TJC\] plus (+) \[0.28\*√SJC\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*PGH\]. Total possible score of 0 to approximately 10, where higher scores represented higher disease activity. Scores below 2.6 indicated clinical remission, score of less than or equals to (\</=) 3.2 indicated low disease activity, score of \</=5.1 indicated moderate disease activity, scores above 5.1 indicated high or severe disease. Rituximab was administered as needed during episodes of inflammation for up to 5 courses. Change from baseline in DAS28 to Week 24 was reported for all 5 courses.

Time frame:
Baseline, Week 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Disease Activity Score Based on 28 Joints (DAS 28) at Week 24
Units on a scaleRituximab
Baseline (n=205)6.6 ± 1.0
Change at Week 24: Course 1 (n=158)-2.3 ± 1.6
Change at Week 24: Course 2 (n=69)-2.4 ± 1.3
Change at Week 24: Course 3 (n=30)-2.8 ± 1.4
Change at Week 24: Course 4 (n=9)-2.6 ± 1.1
Change at Week 24: Course 5 (n=0)NA ± NA
Statistical analysis
  • Rituximab · t-test, 2 sided · p = <0.0001 (Change from baseline in mean DAS28 was analyzed using paired t-test for course 1.)
  • Rituximab · t-test, 2 sided · p = <0.0001 (Change from baseline in mean DAS28 was analyzed using paired t-test for course 2.)
  • Rituximab · t-test, 2 sided · p = <0.0001 (Change from baseline in mean DAS28 was analyzed using paired t-test for course 3.)
  • Rituximab · t-test, 2 sided · p = 0.0001 (Change from baseline in mean DAS28 was analyzed using paired t-test for course 4.)
SecondaryPercentage of Participants Whose DAS28 Improved by Greater Than (>) 1.2 at Week 24

DAS28 score is a measure of participant's disease activity calculated using TJC28, SJC28, PGH \[VAS: 0=no disease activity to 100=maximum disease activity\] and ESR. DAS28 was calculated according to following formula: \[0.56\*√TJC\] + \[0.28\*√SJC\] + \[0.70\*ln ESR\] + \[0.014\*PGH\]. Total possible score of 0 to approximately 10, where higher scores represented higher disease activity. Scores below 2.6 indicated clinical remission, score of \</= 3.2 indicated low disease activity, score of \</= 5.1 indicated moderate disease activity, and scores above 5.1 indicated high or severe disease. Rituximab was administered as needed during episodes of inflammation for up to 5 courses. Change from baseline in DAS28 to Week 24 was reported for all 5 courses. Participants whose DAS28 score improved by 1.2 score were reported.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Whose DAS28 Improved by Greater Than (>) 1.2 at Week 24
Percentage of participantsRituximab
Course 1 (n=158)72.8
Course 2 (n=69)84.1
Course 3 (n=30)86.7
Course 4 (n=9)77.8
Course 5 (n=0)NA
SecondaryPercentage of Participants With EULAR DAS 28 Response at Week 24

Clinical response was assessed according to EULAR categorical DAS28 response criteria, which defined clinically meaningful improvement at Week 24. EULAR response was based on change from baseline (COB) in DAS28 score and also on actual DAS28 score, at Week 24. DAS28 score= participant's disease activity calculated using TJC28, SJC28, PGH \[VAS: 0=no disease activity to 100=maximum disease activity\] and ESR. DAS28 was calculated by following formula: 0.56\*√TJC+(0.28\*√SJC)+(0.70\*ln ESR)+(0.014\*PGH). Total possible score=0-10, higher scores represented higher disease activity. Scores below 2.6: clinical remission, \</=3.2: low disease activity, \</=5.1: moderate disease activity, above 5.1: severe disease. EULAR Good response: DAS28\</=3.2; COB\<-1.2. Moderate response: DAS28\</=3.2 or \>3.2 to \</=5.1 or \>5.1; COB \<-1.2 or \<-0.6 to greater than or equal to (\>/=)-1.2. No response: DAS28 \</=3.2 or \> 3.2 to \</=5.1 or \>5.1; COB \<-0.6 to \>/=-1.2 or \>/=-0.6. EULAR response was reported for 5 courses.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With EULAR DAS 28 Response at Week 24
Percentage of participantsRituximab
Course 1: Good Response (n=164)12.8
Course 1: Moderate Response (n=164)65.9
Course 1: No Response (n=164)21.3
Course 2: Good Response (n=71)8.5
Course 2: Moderate Response (n=71)76.1
Course 2: No Response (n=71)15.5
Course 3: Good Response (n=30)13.3
Course 3: Moderate Response (n=30)76.7
Course 3: No Response (n=30)10.0
Course 4: Good Response (n=9)0.0
Course 4: Moderate Response (n=9)77.8
Course 4: No Response (n=9)22.2
Course 5 (n=0)NA
SecondaryChange From Baseline in Bone Density Score at Weeks 48 and 104

Bone density or bone mineral density (BMD) is the amount of bone mineral in bone tissue. BMD test results are compared to the ideal or peak BMD of a healthy 30-year-old adult, and results are provided as T-score. A score of 0 means BMD is equal to the norm for a healthy young adult. Differences between observed BMD and that of the healthy young adult norm are measured in units called standard deviations (SDs). The more standard deviations below 0, indicated as negative numbers, lower the BMD higher the risk of fracture. SD + 1 to -1 indicates normal BMD; SD between -1 to -2.5 indicates low bone mass, SD -2.5 or lower indicates osteoporosis. Change in bone density was measured in participants who were not treated with biphosphonates by Dual Energy X-Ray Absorptiometry. Change in bone density was assessed at baseline and at Weeks 48 and 104. Change from baseline in bone density score was reported for all 5 courses.

Time frame:
Baseline, Weeks 48 and 104 (End of treatment)
Reported as:
Mean · T-score
Change From Baseline in Bone Density Score at Weeks 48 and 104
T-scoreRituximab
Baseline: Hip T-Score (n=112)-1.08 ± 1.19
Baseline: Spine T-Score (n=109)-1.13 ± 1.26
Change at Week 48: Course 1, Hip T-Score ( n=14)0.09 ± 0.43
Change at Week 48: Course 1, Spine T-Score (n=14)-0.03 ± 0.46
Change at Week 104: Course 1, Hip T-Score (n=11)-0.51 ± 1.60
Change at Week 104: Course 1, Spine T-Score (n=11)0.45 ± 1.73
Change at Week 48: Course 2, Hip T-Score (n=0)NA ± NA
Change at Week 48: Course 2, Spine T-Score (n=0)NA ± NA
Change at Week 104: Course 2, Hip T-Score (n=0)NA ± NA
Change at Week 104: Course 2, Spine T-Score (n=0)NA ± NA
Change at Week 48: Course 3, Hip T-Score (n=0)NA ± NA
Change at Week 48: Course 3, Spine T-Score (n=0)NA ± NA
Change at Week 104: Course 3, Hip T-Score (n=0)NA ± NA
Change at Week 104: Course 3, Spine T-Score (n=0)NA ± NA
Change at Week 48: Course 4, Hip T-Score (n=0)NA ± NA
Change at Week 48: Course 4, Spine T-Score (n=0)NA ± NA
Change at Week 104: Course 4, Hip T-Score (n=0)NA ± NA
Change at Week 104: Course 4, Spine T-Score (n=0)NA ± NA
Change during Course 5 (n=0)NA ± NA

Adverse events

Collected over Baseline up to study withdrawal or Follow-up (Approximately 104 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—70/209 (33.5%)176/209 (84.2%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventRituximab
Rheumatoid arthritisMusculoskeletal and connective tissue disorders11/209
Chest painGeneral disorders8/209
PyrexiaGeneral disorders4/209
PneumoniaInfections and infestations4/209
SyncopeNervous system disorders4/209
PregnancyPregnancy, puerperium and perinatal conditions4/209
CholelithiasisHepatobiliary disorders3/209
Myocardial infarctionCardiac disorders2/209
Abdominal painGastrointestinal disorders2/209
CellulitisInfections and infestations2/209
Most frequent other events
Showing 10 of 13
Most frequent other events
EventRituximab
Back painMusculoskeletal and connective tissue disorders28/209
Rheumatoid arthritisMusculoskeletal and connective tissue disorders25/209
Vitamin D deficiencyMetabolism and nutrition disorders22/209
Upper respiratory tract infectionInfections and infestations21/209
HeadacheNervous system disorders20/209
HypertensionVascular disorders18/209
Urinary tract infectionInfections and infestations15/209
Chest painGeneral disorders14/209
RashSkin and subcutaneous tissue disorders14/209
PyrexiaGeneral disorders12/209

Baseline characteristics

Intent to treat (ITT) population: All participants who had received any part of infusion of study medication. Participants who prematurely withdrew from study for any reason and for whom assessment is not performed for whatever reason were also included in ITT analysis. Due to incomplete database only 209 participants were considered for analysis.

Age, Continuous
Age, Continuous(Years)Rituximab
Mean56.6 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female146
Male63
08

Study locations

16 sites
  • Barzilai; Rheumatology
    Ashkelon, 78306, Israel
  • Soroka Medical Center; Reumatology
    Beer Sheva, 8410101, Israel
  • Assaf Harofe; Dept of Medicine B
    Beer Yaakov, 6093000, Israel
  • Hillel Yaffe MC; Internal C - Rheumatology
    Hadera, 38100, Israel
  • Rambam Medical Center; Rheumatology
    Haifa, 3109601, Israel
  • Bnei Zion Medical Center; Rheumatology
    Haifa, 3339419, Israel
  • Carmel Hospital; Rheumatology Dept
    Haifa, 34362, Israel
  • Wolfson Hospital; Rheumatology
    Holon, 58100, Israel
  • Hadassah Mount Scopus Hospital; Rheumatology
    Jerusalem, 91240, Israel
  • Meir Medical Center; Internal Dept A
    Kfar Saba, 44281, Israel
  • Shaare Zedek Medical Center; Rheumatology Dept
    Naharia, 22100, Israel
  • Nahariya Hospital; Rheumatology Dept
    Nahariya, 22100, Israel
  • EMMS Nazareth; Internal Department A
    Nazareth, 16100, Israel
  • Beilinson Medical Center; Rheumatology
    Petach Tikva, 4941492, Israel
  • Kaplan Medical Center; Reumatology
    Rehovot, 76100, Israel
  • Sourasky / Ichilov Hospital; Rheumatology
    Tel Aviv, 6423906, Israel
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2005 to primary completion in May 2013, 94 months.

Results were first posted in Jun 2016, 3 years after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 94 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2007
First posted
Jul 18, 2007
StartActual
Jun 30, 2005
Primary completionActual
May 26, 2013
CompletionActual
May 26, 2013
Results first posted
Jun 23, 2016
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00503425
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2007
Start date
Jun 30, 2005
Primary completion
May 26, 2013
Completion
May 26, 2013
Results posted
Jun 23, 2016
Last update
Aug 15, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion